New England Peptide, Inc, and SISCAPA Assay Technologies, Inc. Announce Peptide Stable Isotope Standard Collaboration

New England Peptide and SISCAPA expand commercialization of mass spec biomarker assays.

Gardner, MA (PRWEB) June 11, 2014

Today, New England Peptide, Inc. (NEP) and SISCAPA Assay Technologies, Inc. (SAT) announced a collaboration for the manufacture and sale of Stable Isotope Standard (SIS) peptides for use in SISCAPA® protein quantification assays.

Under the terms of the agreement, NEP will manufacture peptide standards suitable for use with SAT’s SISCAPA assays. The peptides will be used together with SAT’s validated monoclonal anti-peptide antibodies to provide SISCAPA licensees standardized, high-sensitivity measurements of proteins by mass spectrometry.

“Protein quantitation by mass spectrometry is rapidly gaining prominence. SISCAPA’s novel platform for the immuno-enrichment of low abundance proteins has lead to the increase of both sensitivity and specificity in MS assays. The technique uses heavy peptides, and as a quality provider of stable isotope peptides since 2001, we are thrilled to work with the thought leaders at SAT”, said Sam Massoni, CEO of NEP.

SISCAPA assays alleviate challenges of limited specificity and protein interferences seen with ligand binding assays and anti-protein immunocapture mass spectrometry. The flexible, multiplex platform has been used to verify clinical utility of candidate protein biomarkers in large sample sets. Laboratory-developed tests (LDT’s) based on SISCAPA technology are in use at a number of clinical reference laboratories and have been validated against tens of thousands of patient samples. The technology is used in pharmaceutical research to study protein pathways and for pharmacokinetic (PK) analysis of biologics including therapeutic antibodies and antibody-drug complexes (ADCs).

“We at SAT believe this is the next logical step in bringing SISCAPA technology to the clinical and life-science market. As our menu of validated SISCAPA tests continues to expand, mass spectrometry customers, who are accustomed to very high precision, need the highest quality peptide internal standards. We feel that NEP brings that to our growing customer base”, said Selena Larkin, the Vice President of Marketing and Sales at SAT.

About SISCAPA Assay Technologies, Inc. (SAT) 
SISCAPA Assay Technologies Inc. (SAT) delivers tools for development of high-sensitivity, high-throughput specific assays for proteins, including clinical biomarkers, using SISCAPA® (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology. SISCAPA is a registered trademark of SISCAPA Assay Technologies Inc. in the United States and/or other countries. Additional information about SISCAPA technology, reagents and licensing is available at

About New England Peptide (NEP) 
New England Peptide, founded in 1998, designs and manufactures peptides, polyclonal antibodies and monoclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunology experts specialize in delivering a full range of services for biotech and pharmaceutical applications. More information on NEP can be found at


"NEP provides antibodies that work (when all others fail) and has advised on peptides that have taken my research to new levels. There is nothing like working with NEP in terms of the comfort and assurance of attaining quality results. They are the best!"
Steven G. PhD - NX PharmaGen